Dymicron was selected as an Innovator in the Innovator Pavilion at the #LSIUSA23 Emerging Medtech Summit. Ted Bird, Chief Strategy Officer at Dymicron will be attending and meeting with the MedTech community at this event.
Ted is passionate about innovative medical device technology which provides meaningful improvements to patient lives. He is a spine industry expert, with over 32 years of global commercial and executive leadership experience with market leading spine companies including Medtronic, JNJ, Orthofix, ApiFix and Titan Spine.
Dymicron is advancing a new artificial cervical total disc replacement implant made from polycrystalline diamond — which generates no detectable wear debris. The unique biomechanical design of the Triadyme-C disc also replicates the natural motion and mobility of a normal disc.
Dymicron Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Dymicron Inc.